<DOC>
	<DOC>NCT00372723</DOC>
	<brief_summary>To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.</brief_summary>
	<brief_title>Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)</brief_title>
	<detailed_description>This is a pilot (preliminary) study. Patients with a diagnosis of TEN will be asked to consider participating. The study intervention is a single intravenous dose of remicaide (5 mg/kg). Standard supportive care will be given. The percentage of patients alive at 30 days after treatment with remicaide will be compared to historical controls.</detailed_description>
	<mesh_term>Stevens-Johnson Syndrome</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Admission to burn unit with a histologic diagnosis of TENs Pregnancy hypersensitivity to remicaide history of heart failure documented bacteremia history of cancer inability to consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>toxic epidermal necrlysis</keyword>
	<keyword>ten</keyword>
</DOC>